A detailed history of Benjamin F. Edwards & Company, Inc. transactions in Coll Plant Biotechnologies LTD stock. As of the latest transaction made, Benjamin F. Edwards & Company, Inc. holds 39,760 shares of CLGN stock, worth $165,004. This represents 0.0% of its overall portfolio holdings.

Number of Shares
39,760
Previous 50,450 21.19%
Holding current value
$165,004
Previous $272,000 27.57%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 12, 2024

SELL
$4.84 - $6.75 $51,739 - $72,157
-10,690 Reduced 21.19%
39,760 $197,000
Q1 2024

Apr 29, 2024

BUY
$4.72 - $6.15 $1,416 - $1,845
300 Added 0.6%
50,450 $272,000
Q4 2023

Feb 06, 2024

BUY
$4.97 - $6.64 $25,347 - $33,864
5,100 Added 11.32%
50,150 $320,000
Q3 2023

Nov 13, 2023

SELL
$5.4 - $8.05 $22,464 - $33,488
-4,160 Reduced 8.45%
45,050 $254,000
Q2 2023

Aug 15, 2023

SELL
$6.6 - $8.23 $110,226 - $137,449
-16,701 Reduced 25.34%
49,210 $399,000
Q1 2023

Apr 27, 2023

BUY
$6.74 - $12.99 $32,763 - $63,144
4,861 Added 7.96%
65,911 $463,000
Q4 2022

Feb 07, 2023

SELL
$4.71 - $9.5 $20,535 - $41,420
-4,360 Reduced 6.67%
61,050 $510,000
Q3 2022

Oct 28, 2022

SELL
$6.3 - $9.99 $40,320 - $63,936
-6,400 Reduced 8.91%
65,410 $447,000
Q2 2022

Aug 12, 2022

SELL
$8.0 - $11.19 $27,680 - $38,717
-3,460 Reduced 4.6%
71,810 $585,000
Q1 2022

May 04, 2022

BUY
$8.97 - $16.4 $148,686 - $271,846
16,576 Added 28.24%
75,270 $861,000
Q4 2021

Feb 07, 2022

BUY
$12.0 - $22.48 $12,600 - $23,604
1,050 Added 1.82%
58,694 $960,000
Q3 2021

Nov 02, 2021

SELL
$16.0 - $21.75 $111,840 - $152,032
-6,990 Reduced 10.81%
57,644 $973,000
Q2 2021

Aug 11, 2021

BUY
$13.55 - $22.45 $875,790 - $1.45 Million
64,634 New
64,634 $1.37 Million

Others Institutions Holding CLGN

About CollPlant Biotechnologies Ltd


  • Ticker CLGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 11,086,500
  • Market Cap $46M
  • Description
  • CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, and Europe. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering tech...
More about CLGN
Track This Portfolio

Track Benjamin F. Edwards & Company, Inc. Portfolio

Follow Benjamin F. Edwards & Company, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Benjamin F. Edwards & Company, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Benjamin F. Edwards & Company, Inc. with notifications on news.